Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 120,109

Document Document Title
WO/2016/176571A1
The present invention relates to compounds of Formula (la) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods us...  
WO/2016/172952A1
Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIIIα inhibitor to treat Alzheimer's disease. Further, also provided is a method for screening a drug treating Alzheimer's disease by whether A...  
WO/2016/176437A1
Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and/or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive perform...  
WO/2016/174661A1
The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.  
WO/2016/175646A1
The invention relates to a novel method for producing a nutraceutical amaranth formulation from whole amaranth grain. The resulting nutraceutical amaranth formulation has unique properties that can be used to solve problems of particular...  
WO/2016/176118A1
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.  
WO/2016/175236A1
The present invention addresses the problem of obtaining an anti-repulsive guidance molecule a (RGMa) antibody which has a high binding activity and few side effects and can be used as a medicine for preventing, treating, or preventing t...  
WO/2016/176460A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [formula (I) should be inserted here]. Also provided herein are pharmaceutical compositions comprising compounds of Formu...  
WO/2016/176562A1
Provided herein are compounds and pharmaceutical compositions comprising EphA4 inhibitors. The EphA4 inhibitors and compositions thereof are useful for the treatment of ALS.  
WO/2016/174496A1
The invention includes a new class of radiolabeled compounds of formula I able to bind P-glycoprotein with high affinity and selectivity. The protein prevents accumulation in the brain of a wide range of drugs and, changes in P-gp expres...  
WO/2016/169028A1
The present invention provides three novel conotoxin peptides, namely κ-CPTx-btl06, κ-CPTx-btl07 and κ-CPTx-btl08, amino acid sequences thereof being shown as SEQ ID NO: 1, 2 and 3 respectively. The present invention also relates to p...  
WO/2016/171248A1
Provided is a compound that possibly has an orexin receptor antagonist activity and, therefore, is expected to be useful as a medicine for preventing or treating sleep disorder, depression, anxiety disorder, panic disorder, integration d...  
WO/2016/172437A2
In accordance with one or more embodiments, the present invention provides a compound of formulas I, II, and III, for use in methods of inhibition of PBX1-DNA interaction in a mammalian cell or population of cells, and for use in the tre...  
WO/2016/169421A1
The present invention relates to an imidazo isoindole derivative, a preparation method therefor and a medical use thereof. In particular, the present invention relates to the imidazo isoindole derivative as shown in the formula (I), a pr...  
WO/2016/169453A1
A nerve growth factor composition and a powder injection. The composition consists of a nerve growth factor, a stabilizer, a pH buffer, and water. The stabilizer is one of sorbierite, dextran, trehalose, raffinose and mannitol. The use o...  
WO/2016/169902A1
The present invention relates to compounds of formula (I), wherein R1' is CH3 R1' is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1, and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethy...  
WO/2016/169698A1
The present invention relates to a compound reducing microtubule detyrosination in axonal tips selected from the group consisting of tubulin carboxypeptidase inhibitors and tubulin tyrosine ligase activators and combinations thereof for ...  
WO/2016/171181A1
Provided are fused pyrazole derivatives and pharmaceutically acceptable salts thereof that act at high selectivity on dopamine D4 receptors and are useful as agents for the treatment of attention deficit-hyperactivity disorder and the li...  
WO/2016/170501A1
A new therapeutic use of botulinum neurotoxin serotype A (Bont/A) is described, therapeutic treatment of paralysis caused by spinal cord injury.  
WO/2016/171249A1
Provided is the compound represented by formula (I) (in the formula, Y1 is O or the like; Z1 is, C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently hydrogen atoms or the like; R1 is a s...  
WO/2016/169663A1
Crystalline salts of 7,8-Didehydro-4,5 alpha-epoxy-17-methylmorphinan-3,6 alpha-diol sulfate(2:1), i.e. of morphine sulphate, are disclosed and four polymorphic forms of these salts are reported. The invention further relates to a pharma...  
WO/2016/169455A1
A nerve growth factor composition and a powder injection. The nerve growth factor composition consists of a nerve growth factor, a stabilizer, a supporting agent, a pH buffer, and water. The stabilizer is arginine, glutamic acid, glycine...  
WO/2016/170064A1
The present invention provides imidazotriazinones of formula (I) as PDEl inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2016/172333A1
The present disclosure relates to solid state forms of Perampanel, processes for preparation thereof and pharmaceutical compositions thereof.  
WO/2016/169454A1
A nerve growth factor composition and a powder injection. The nerve growth factor composition comprises the following components: 10μg/mL to 100μg/mL of nerve growth factor, 10mg/mL to 80mg/mL of disaccharide stabilizer, 0mg/mL to 30mg...  
WO/2016/171549A1
The present invention describes a compound for use in treating or preventing glutamate excitotoxicity and/or tauopathy in a subject, preferably a disorder selected from the group of epilepsy, spinal cord injury, stroke, traumatic brain i...  
WO/2016/172437A3
In accordance with one or more embodiments, the present invention provides a compound of formulas I, II, and III, for use in methods of inhibition of PBX1-DNA interaction in a mammalian cell or population of cells, and for use in the tre...  
WO/2016/170009A1
The present invention relates to novel aminoindazolyl derivative compounds of Formula(I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions con...  
WO/2016/166684A1
The present invention relates to compounds of the general form (I). The present invention relates to new substituted diazepino-indole derivatives of the general formula (I), and to pharmaceutically acceptable salts thereof, as well as to...  
WO/2016/165770A1
The present invention refers to a 4-phenylbutyric acid derivative of Formula (1), wherein Y is selected from 0 or H2; R1 is selected from N2 or H; R2 is a radical of an amino acid, a salicylic acid, a 4- phenylbutyric acid, a catechol, o...  
WO/2016/168757A1
This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversio...  
WO/2016/168450A1
The present invention provides a compound having the structure: wherein X is C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, cyano, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkenylaryl, alkenylheteroaryl, alkynylaryl, alkynylheteroary...  
WO/2016/167365A1
Provided is a marker for determining a mental disease, which can be used for an objective diagnosis of a mental disease. A marker for determining a metal disease, which comprises at least one enterobacterium selected from those belonging...  
WO/2016/166679A1
The present invention concerns an acetylcholinesterase inhibitor for use in the treatment or prevention of side effects caused by the administration of an antipsychotic agent in a patient suffering from psychiatric disorders associated w...  
WO/2016/164977A1
The present specification teaches generally a method for the treatment or prophylaxis of a male-biased neurological disorder in male subjects.  
WO/2016/167263A1
In a non-limiting embodiment, a pharmaceutical composition for the prevention and/or treatment of atopic dermatitis is provided, the pharmaceutical composition containing an IL-31 antagonist as an active ingredient, wherein 0.1-1000 mg/b...  
WO/2016/168615A1
Disclosed are methods of treating or preventing demyelination in a mammal, the method comprising administering to the mammal a (1) thrombin inhibitor or (2) compound that stimulates astrocytes in the mammal to (i) release a thrombin inhi...  
WO/2016/167944A2
The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyal...  
WO/2016/168197A1
Compositions and methods for improved delivery of active agents to the brain are provided. The compositions typically include a nanocarrier, such as a polymeric nanoparticle, liposome, or nanolipagel or are in the form of a conjugate. Th...  
WO/2016/167528A1
The present invention relates to a method for converting human fibroblasts into neural stem cells and, more specifically, to a method for directly converting human fibroblasts into neural stem cells using only a combination of small mole...  
WO/2016/165101A1
The present invention provides a peptide with sequence of DEAQETAVSSHEQD, a fragment of rabbit-α1 antiproteinase F, and its derivatives DEAQETAVSSHEQ and QETACSSHEQD, which significantly inhibit serum-borne HCV replication in hADSC and ...  
WO/2016/168580A1
Bolaamphiphilic compounds are provided according to formula (I); where HG1, HG2 and L1 are as defined herein. Provided bolaamphiphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into anima...  
WO/2016/168762A3
The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, ...  
WO/2016/166078A1
The invention relates to pyridopyrimidinone compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, R, R2, R3, R4, R5 and R6 are as defined herein, as well as pharmaceutical compositions comprising such compound...  
WO/2016/167345A1
The present invention provides a transdermal patch provided with a support and an adhesive layer layered on the support, the adhesive layer including ropinirole or a pharmacologically acceptable salt thereof, an organic amine or an acid ...  
WO/2016/168760A1
This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversio...  
WO/2016/166565A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to prevent, treat of delay the progression of α-synucleinopathies, including Parkinson disease.  
WO/2016/168658A1
In some aspects, the disclosure relates to the reactivation of inactive X chromosomes (Xi). In some embodiments, the disclosure provides compositions and methods for the reactivation of inactive X chromosomes. In some embodiments, the co...  
WO/2016/167385A1
The present invention relates to a composition for preventing or treating Alzheimer's disease comprising lycopodiella cernua extract or a compound isolated therefrom. The lycopodiella cernua extract or the compound isolated therefrom has...  
WO/2016/167318A1
Provided are: a memory-improving agent and memory-improving composition containing as an active ingredient a compound that is an inverse agonist of opioid δ receptors, a pharmacologically acceptable salt thereof, or a solvate of these; ...  

Matches 301 - 350 out of 120,109